Ally Bridge Group, a Chinese-based global healthcare-focused investment platform, has expanded its global pharmaceutical portfolio with several recent investments in therapeutics companies based in China, Europe and the US.
The Chinese investment firm said it plans to work closely with these companies by taking active board of directors and/or scientific advisory board positions.
In the US, Ally Bridge Group completed investments in four companies including:
- V Biosciences (www.3vbio.com), is an oncology drug development company based inMenlo Park, California, targeting fatty acid synthase (FASN) in various solid tumors.
- Symic Biomedical (www.symicbio.com), is a San Francisco-based company specialising in the development of a novel category of therapeutics treating osteoarthritis and vascular diseases.
- Alzheon (www.alzheon.com), a Boston-based clinical-stage therapeutics company developing a first-in-class treatment for Alzheimer’s disease, which represents ABG’s first neurology therapeutics investment.
- ImmunGene (www.immungene.com), an existing Ally Bridge Group portfolio company based Thousand Oaks, California, which has developed a unique empowered antibody therapeutics technology platform based on antibody-interferon fusion molecules.
“Ally Bridge Group, while continuing to build out its oncology, especially immuno-oncology, portfolio in both the US and Europe, has also established strategic footholds in other large therapeutic areas, such as diabetes, neurology and inflammation. All of these investments, together with our existing specialty-pharma portfolio in the U.S., have strengthened and diversified ABG’s global biopharmaceutical reach,” said Frank Yu, ABG’s Founder, CEO and CIO.
“With our roots in Asia, and our investments in the US and Europe, we are becoming a truly global healthcare investment platform that differentiates itself by enabling partnerships between emerging healthcare companies and industry leaders, and by acting as a bridge between China and the US.”